DNA nanostructure-based drug delivery nanosystems in cancer therapy

The objective of this review is to make a retrospect and summary about these different kinds of DNA nanostructure-based drug delivery nanosystems and their latest progresses: (1) active targeting; (2) mutidrug co-delivery; (3) construction of stimuli-responsive/intelligent nanosystems. Graphical abstract
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research

Related Links:

By CHARLES SILVER and DAVID A.HYMAN Today THCB is happy to publish a piece reflecting the learnings from Charles Silver and David Hyman’s forthcoming book Overcharged: Why Americans Pay Too Much For Health Care, shortly to be published by the libertarian leaning Cato Institute. In subsequent weeks we’ll feature commentary from the right (Michael Cannon) and from the left (Andy Slavitt) about the book and its proposals. For now please give your views in the comments–Matthew Holt There are many reasons why the United States is “the most expensive place in the world to get sick.” In Par...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Economics OP-ED Cato Institute Charles Silver David A. Hyman Obamacare Overcharged Source Type: blogs
Elekta (STO:EKTA B) said today it won CE Mark approval in the European Union for its Elekta Unity magnetic resonance radiation therapy system. The Stockholm-based company touted that its Unity system allows clinicians to deliver radiation doses while simultaneously visualizing the tumor and surrounding tissue through MR imaging. The system also features integrated advanced tools that allow the operator to adapt treatment based on anatomical information. “Unity is a tremendous innovation in patient care, one that enables a scan-plan-treat approach to developing tailored regimens that should yield substantive clinical ...
Source: Mass Device - Category: Medical Devices Authors: Tags: Imaging Oncology Regulatory/Compliance Elekta Source Type: news
Baltimore biotechnology firm WindMIL Therapeutics has raised a $32.5 million to support clinical trials and further development for new cancer therapies. The Series B round was led by QiMing USA Venture Partners, the new U.S. entity of China firm QiMing. WindMIL, a cell therapy company, is previously backed by about $11 million in funding. WindMIL was founded out of Johns Hopkins University by researchers Kimberly Noonan and Dr. Ivan Borrello. Th e clinical stage company is working to develop…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
In this study, p53 wildtype (LoVo) and human p53 mutated (HT29 and SW480) colorectal cancer cells were treated with the miniFlatPlaSter - a device particularly developed for the treatment of tumor cells - that uses the Surface Micro Discharge (SMD) technology for plasma production in air. The present study analyzed the effects of plasma on colorectal cancer cells in vitro and on normal colon tissue ex vivo. Plasma treatment had strong effects on colon cancer cells, such as inhibition of cell proliferation, induction of cell death, and modulation of p21 expression. In contrast, CAP treatment of murine colon tissue ex vivo f...
Source: Biological Chemistry - Category: Chemistry Tags: Biol Chem Source Type: research
AbstractImmune checkpoint antagonists (CTLA-4 and PD-1/PD-L1) and CAR T-cell therapies generate unparalleled durable responses in several cancers and have firmly established immunotherapy as a new pillar of cancer therapy. To extend the impact of immunotherapy to more patients and a broader range of cancers, targeting additional mechanisms of tumor immune evasion will be critical. Adenosine signaling has emerged as a key metabolic pathway that regulates tumor immunity. Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment. Hypoxia, high cell turnover, and expression of CD39 ...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
This study sought to develop a simple nanoparticle-based approach to enhance the efficiency and tolerability of lipopolysaccharide (LPS), a potent ligand of Toll-like Receptor 4 (TLR4), for immunotherapy in cancer. Despite holding promise within this context, the strong pro-inflammatory properties of LPS also account for its low tolerability given localized and systemic side effects, which restrict the administrable dosage. Herein, we investigated the effect of LPS decoration as a surface-active molecule on a polymeric matrix upon its efficiency and tolerability. The LPS-decorated nanoparticles (LPS-NP) were about 150&thin...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Review article Source Type: research
Publication date: 25 August 2018 Source:International Journal of Pharmaceutics, Volume 547, Issues 1–2 Author(s): Yumeng Jiang, Tao Li, Meiling Lu, Dan Li, Fazheng Ren, Huiying Zhao, Yuan Li There is an urgent need for developing nanocarrier of excellent biocompatibility which can selectively release drugs at desired locations that can increase intratumoral drug concentration and reduce side effects. Herein, we developed a highly biocompatible nanocarrier made of oxidized starch in delivering doxorubicin (DOX) for enhanced anti-cancer therapy. The 30% oxidized starch can spontaneously self-assemble into 30–50...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Authors: Yamamoto Y, Sasaki N, Kumagai K, Takeuchi S, Toyooka T, Otani N, Wada K, Narita Y, Ichimura K, Namba H, Mori K, Tomiyama A Abstract Glioblastoma (GBM) still carries a poor prognosis due to the refractoriness against antitumor drugs. Temozolomide (TMZ), one of the few standard therapy drugs against GBM worldwide, has only limited effect due to acquired TMZ resistance of GBM. Therefore, development of novel therapeutic methods to overcome the TMZ resistance of GBM is urgent. The brain is the most cholesterol-rich organ in the human body, so modulation of cholesterol in tumor cells originating from the brain ...
Source: Neurologia Medico-Chirurgica - Category: Neurosurgery Tags: Neurol Med Chir (Tokyo) Source Type: research
We describe development of a new nanoconstruct composed of gold nanorods (GNRs) conjugated to carbonic anhydrase IX (CAIX) antibody that specifically binds to CAIX, a biomarker of hypoxia, to facilitate targeting tumor hypoxic areas for focused photothermal ablation. Physicochemical characterization studies confirmed the size, shape, monodispersity, surface charge, and serum stability of the GNRs. Enzyme-linked immunosorbent assays and cellular binding and uptake studies confirmed successful conjugation of antibody to the GNRs and specificity for CAIX. Near-infrared irradiation of CAIX-overexpressing cells treated with GNR...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Drugs & Pharmacology | Nanotechnology | National Institute for Health and Clinical Excelle | Study | Toxicology